

TDMS No. 99031 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 04/13/2011

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

F1_M3

C Number: C99031
Lock Date: 05/05/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.3.1
PWG Approval Date: NONE

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|------------------|---------|-----------|-----------|------------|
|------------------|---------|-----------|-----------|------------|

Disposition Summary

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Accidentally Killed | | | 1 | |
| Moribund Sacrifice | 8 | 16 | 23 | 13 |
| Natural Death | 8 | 7 | 5 | 14 |
| Survivors | | | | |
| Terminal Sacrifice | 34 | 27 | 21 | 23 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|------------------------------------|----------|----------|----------|----------|
| Esophagus | (50) | (50) | (50) | (50) |
| Gallbladder | (46) | (48) | (44) | (46) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Carcinoma | | | 1 (2%) | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Carcinoma | 1 (2%) | | 1 (2%) | 2 (4%) |
| Serosa, Hepatoblastoma | | 1 (2%) | | |
| Liver | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | 9 (18%) | 2 (4%) | | 3 (6%) |
| Hemangiosarcoma, Multiple | | 1 (2%) | | |
| Hepatoblastoma | 2 (4%) | 16 (32%) | 10 (20%) | 17 (34%) |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) |
| Hepatoblastoma, Multiple | 1 (2%) | 12 (24%) | 26 (52%) | 21 (42%) |
| Hepatocellular Adenoma | 13 (26%) | 6 (12%) | 7 (14%) | 6 (12%) |
| Hepatocellular Adenoma, Multiple | 18 (36%) | 40 (80%) | 26 (52%) | 27 (54%) |
| Hepatocellular Carcinoma | 11 (22%) | 8 (16%) | 9 (18%) | 4 (8%) |
| Hepatocellular Carcinoma, Multiple | 11 (22%) | 23 (46%) | 32 (64%) | 43 (86%) |
| Hepatocholangiocarcinoma | | 1 (2%) | | |
| Hepatocholangiocarcinoma, Multiple | | 1 (2%) | | 1 (2%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|---|---------|-----------|-----------|------------|
| Ito Cell Tumor Benign | | 1 (2%) | | |
| Ito Cell Tumor Benign, Multiple | 1 (2%) | | | |
| Mesentery | (5) | (6) | (3) | (4) |
| Hepatoblastoma, Metastatic, Liver | | 2 (33%) | 1 (33%) | 1 (25%) |
| Hepatocholangiocarcinoma, Metastatic, Liver | | | | 1 (25%) |
| Pancreas | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | 1 (2%) | 1 (2%) | |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | | 1 (2%) | | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Squamous Cell Papilloma | | 2 (4%) | 1 (2%) | |
| Squamous Cell Papilloma, Multiple | | | | 1 (2%) |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Tooth | (50) | (50) | (50) | (50) |

CARDIOVASCULAR SYSTEM

| | | | | |
|---|--------|--------|------|--------|
| Blood Vessel | (50) | (50) | (50) | (50) |
| Heart | (50) | (50) | (50) | (50) |
| Hemangiosarcoma, Metastatic, Liver | 1 (2%) | 1 (2%) | | |
| Hepatoblastoma, Metastatic, Liver | | 1 (2%) | | |
| Hepatocholangiocarcinoma, Metastatic, Liver | | | | 1 (2%) |

ENDOCRINE SYSTEM

| | | | | |
|-----------------------------------|--------|--------|--------|--------|
| Adrenal Cortex | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | | 1 (2%) | |
| Subcapsular, Adenoma | 1 (2%) | 3 (6%) | 1 (2%) | |
| Adrenal Medulla | (50) | (50) | (50) | (49) |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Adenoma | 1 (2%) | | | |
| Parathyroid Gland | (36) | (46) | (46) | (44) |
| Pituitary Gland | (49) | (50) | (50) | (49) |
| Thyroid Gland | (49) | (49) | (50) | (50) |
| C-cell, Carcinoma | | | 1 (2%) | 1 (2%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|--------------------------|---------|-----------|-----------|------------|
| Follicular Cell, Adenoma | | | 2 (4%) | 2 (4%) |

GENERAL BODY SYSTEM

| | | | | |
|------------|-----|-----|-----|-----|
| Peritoneum | (0) | (1) | (2) | (2) |
|------------|-----|-----|-----|-----|

GENITAL SYSTEM

| | | | | |
|--|--------|--------|--------|--------|
| Epididymis | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | 1 (2%) | | |
| Bilateral, Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) |
| Preputial Gland | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | | | | 1 (2%) |
| Prostate | (50) | (50) | (49) | (50) |
| Adenoma | | | | 1 (2%) |
| Carcinoma | | 1 (2%) | | |
| Hemangiosarcoma | | 1 (2%) | | |
| Seminal Vesicle | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | | 1 (2%) | |
| Testes | (50) | (50) | (50) | (50) |
| Interstitial Cell, Adenoma | 1 (2%) | | 1 (2%) | 1 (2%) |

HEMATOPOIETIC SYSTEM

| | | | | |
|--|------|--------|--------|--------|
| Bone Marrow | (50) | (50) | (50) | (50) |
| Hemangioma | | | 1 (2%) | |
| Lymph Node | (11) | (15) | (18) | (14) |
| Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | | 1 (7%) | | |
| Bronchial, Hepatoblastoma, Metastatic, Liver | | 1 (7%) | | |
| Bronchial, Hepatocholangiocarcinoma, Metastatic, Liver | | | | 1 (7%) |
| Lymph Node, Mandibular | (50) | (50) | (50) | (50) |
| Carcinoma, Metastatic, Harderian Gland | | | 1 (2%) | |
| Lymph Node, Mesenteric | (50) | (49) | (49) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|--|----------|-----------|-----------|------------|
| Hepatoblastoma, Metastatic, Liver | | | 1 (2%) | 1 (2%) |
| Spleen | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | | 1 (2%) | | 1 (2%) |
| Thymus | (50) | (47) | (50) | (45) |
| Thymoma Malignant | | 1 (2%) | | |
| INTEGUMENTARY SYSTEM | | | | |
| Skin | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) |
| Pinna, Amelanotic Melanoma, Malignant | | | | 1 (2%) |
| Pinna, Melanoma Malignant | 1 (2%) | | | |
| Tail, Schwannoma Nos | | | | 1 (2%) |
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (50) | (50) | (50) | (50) |
| Turbinates, Carcinoma, Metastatic, Harderian Gland | | | 1 (2%) | |
| Skeletal Muscle | (1) | (1) | (1) | (1) |
| Hepatoblastoma, Metastatic, Liver | | 1 (100%) | | |
| NERVOUS SYSTEM | | | | |
| Brain | (50) | (50) | (50) | (50) |
| Neuroblastoma | | | 1 (2%) | |
| Peripheral Nerve | (0) | (0) | (1) | (0) |
| RESPIRATORY SYSTEM | | | | |
| Lung | (50) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Adenoma | 8 (16%) | 6 (12%) | 5 (10%) | 1 (2%) |
| Alveolar/Bronchiolar Carcinoma | 11 (22%) | 7 (14%) | 4 (8%) | 3 (6%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|---|----------|-----------|-----------|------------|
| Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | 2 (4%) | | | |
| Alveolar/Bronchiolar Carcinoma, Multiple Carcinoma, Metastatic, Harderian Gland | | 1 (2%) | 1 (2%) | |
| Hemangiosarcoma | 1 (2%) | | 1 (2%) | |
| Hepatoblastoma, Metastatic, Liver | | 7 (14%) | 14 (28%) | 14 (28%) |
| Hepatocellular Carcinoma, Metastatic, Liver | 10 (20%) | 8 (16%) | 8 (16%) | 18 (36%) |
| Hepatocholangiocarcinoma, Metastatic, Liver | | 1 (2%) | | 1 (2%) |
| Nose | (50) | (50) | (50) | (50) |
| Trachea | (50) | (50) | (50) | (50) |

SPECIAL SENSES SYSTEM

| | | | | |
|-----------------------------------|--------|---------|--------|----------|
| Ear | (1) | (0) | (0) | (1) |
| Neural Crest Tumor | | | | 1 (100%) |
| Eye | (50) | (50) | (50) | (50) |
| Harderian Gland | (50) | (50) | (50) | (50) |
| Adenoma | 4 (8%) | 3 (6%) | 2 (4%) | 3 (6%) |
| Carcinoma | 3 (6%) | 5 (10%) | 4 (8%) | 2 (4%) |
| Hepatoblastoma, Metastatic, Liver | | | 1 (2%) | |

URINARY SYSTEM

| | | | | |
|-----------------------------------|------|--------|------|--------|
| Kidney | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | 1 (2%) | | 1 (2%) |
| Urethra | (0) | (1) | (0) | (0) |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | | 1 (2%) | | |

SYSTEMIC LESIONS

| | | | | |
|--------------------|--------|--------|--------|-------|
| Multiple Organ | *(50) | *(50) | *(50) | *(50) |
| Lymphoma Malignant | 1 (2%) | 3 (6%) | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| | | | | |
|------------------|---------|-----------|-----------|------------|
| B6C3F1 MICE MALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|------------------|---------|-----------|-----------|------------|

Tumor Summary for Males

| | | | | |
|--|----|-----|-----|-----|
| Total Animals with Primary Neoplasms (b) | 44 | 48 | 48 | 49 |
| Total Primary Neoplasms | 99 | 148 | 137 | 144 |
| | | | | |
| Total Animals with Benign Neoplasms | 38 | 47 | 36 | 35 |
| Total Benign Neoplasms | 47 | 61 | 46 | 42 |
| | | | | |
| Total Animals with Malignant Neoplasms | 35 | 46 | 46 | 48 |
| Total Malignant Neoplasms | 52 | 87 | 91 | 100 |
| | | | | |
| Total Animals with Metastatic Neoplasms | 13 | 17 | 23 | 26 |
| Total Metastatic Neoplasms | 13 | 26 | 31 | 42 |
| | | | | |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | | |
| | | | | |
| Total Animals with Neoplasms Uncertain- Benign or Malignant | | | | 2 |
| Total Uncertain Neoplasms | | | | 2 |

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE FEMALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|--------------------|---------|-----------|-----------|------------|
|--------------------|---------|-----------|-----------|------------|

Disposition Summary

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Accidentally Killed | | 2 | | |
| Dosing Accident | 5 | | 1 | |
| Moribund Sacrifice | 8 | 8 | 3 | 3 |
| Natural Death | 6 | 4 | 3 | 11 |
| Survivors | | | | |
| Terminal Sacrifice | 31 | 36 | 43 | 36 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | |
|------------------------------------|----------|----------|----------|----------|
| Esophagus | (50) | (50) | (50) | (50) |
| Gallbladder | (50) | (50) | (48) | (48) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Liver | (50) | (50) | (50) | (50) |
| Fibrous Histiocytoma | | | | 1 (2%) |
| Hemangiosarcoma | | 1 (2%) | 1 (2%) | |
| Hepatoblastoma | 1 (2%) | 1 (2%) | 7 (14%) | 7 (14%) |
| Hepatoblastoma, Multiple | | | 1 (2%) | 4 (8%) |
| Hepatocellular Adenoma | 7 (14%) | 7 (14%) | 4 (8%) | 5 (10%) |
| Hepatocellular Adenoma, Multiple | 10 (20%) | 30 (60%) | 37 (74%) | 43 (86%) |
| Hepatocellular Carcinoma | 7 (14%) | 8 (16%) | 10 (20%) | 13 (26%) |
| Hepatocellular Carcinoma, Multiple | 2 (4%) | 2 (4%) | 5 (10%) | 31 (62%) |
| Osteosarcoma, Metastatic, Bone | | | | 1 (2%) |
| Mesentery | (3) | (5) | (3) | (4) |
| Oral Mucosa | (1) | (0) | (0) | (0) |
| Gingival, Squamous Cell Carcinoma | 1 (100%) | | | |
| Pancreas | (50) | (49) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE FEMALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|---------------------------|---------|-----------|-----------|------------|
| Fibrous Histiocytoma | | | | 1 (2%) |
| Salivary Glands | (50) | (50) | (49) | (50) |
| Sarcoma, Metastatic, Skin | | 1 (2%) | | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |
| Squamous Cell Papilloma | 2 (4%) | 1 (2%) | | |
| Stomach, Glandular | (50) | (50) | (50) | (50) |
| Adenoma | | | 1 (2%) | |
| Tooth | (50) | (50) | (50) | (50) |

CARDIOVASCULAR SYSTEM

| | | | | |
|--------------|------|------|------|------|
| Blood Vessel | (50) | (49) | (50) | (50) |
| Heart | (50) | (50) | (50) | (50) |

ENDOCRINE SYSTEM

| | | | | |
|----------------------------|--------|--------|--------|--------|
| Adrenal Cortex | (50) | (50) | (50) | (50) |
| Fibrous Histiocytoma | | | | 1 (2%) |
| Adrenal Medulla | (50) | (50) | (50) | (50) |
| Pheochromocytoma Benign | | 1 (2%) | | |
| Pheochromocytoma Malignant | | 1 (2%) | | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) |
| Parathyroid Gland | (47) | (46) | (45) | (45) |
| Pituitary Gland | (50) | (50) | (49) | (50) |
| Pars Distalis, Adenoma | 4 (8%) | 2 (4%) | 1 (2%) | |
| Pars Intermedia, Adenoma | 1 (2%) | | | 1 (2%) |
| Thyroid Gland | (49) | (48) | (49) | (48) |

GENERAL BODY SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE FEMALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|----------------------------|---------|-----------|-----------|------------|
| GENITAL SYSTEM | | | | |
| Clitoral Gland | (50) | (50) | (50) | (49) |
| Ovary | (50) | (50) | (49) | (50) |
| Choriocarcinoma | 1 (2%) | | | |
| Cystadenoma | 2 (4%) | 3 (6%) | 1 (2%) | 1 (2%) |
| Fibrous Histiocytoma | | | | 1 (2%) |
| Hemangioma | | | | 1 (2%) |
| Hemangiosarcoma | 1 (2%) | | | |
| Teratoma Benign | | | 1 (2%) | |
| Uterus | (50) | (50) | (50) | (50) |
| Polyp Stromal | 1 (2%) | | | |
| Sarcoma Stromal | 1 (2%) | | | |
| Endometrium, Polyp Stromal | | | 1 (2%) | |

HEMATOPOIETIC SYSTEM

| | | | | |
|------------------------|--------|------|------|------|
| Bone Marrow | (50) | (50) | (50) | (50) |
| Lymph Node | (16) | (11) | (11) | (6) |
| Lymph Node, Bronchial | (0) | (0) | (0) | (1) |
| Lymph Node, Mandibular | (49) | (50) | (49) | (50) |
| Lymph Node, Mesenteric | (50) | (50) | (50) | (50) |
| Spleen | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | 1 (2%) | | | |
| Thymus | (50) | (49) | (49) | (50) |

INTEGUMENTARY SYSTEM

| | | | | |
|----------------------|--------|--------|--------|--------|
| Mammary Gland | (50) | (50) | (50) | (50) |
| Carcinoma | | 1 (2%) | 1 (2%) | |
| Skin | (50) | (50) | (50) | (50) |
| Basal Cell Carcinoma | 1 (2%) | | | |
| Keratoacanthoma | | | | 1 (2%) |
| Melanoma Malignant | 1 (2%) | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE FEMALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|--------------------|---------|-----------|-----------|------------|
|--------------------|---------|-----------|-----------|------------|

| | | | | |
|------------------------------|--------|--------|--------|--|
| Sarcoma | 1 (2%) | 1 (2%) | | |
| Subcutaneous Tissue, Sarcoma | 2 (4%) | 2 (4%) | | |
| Tail, Fibrous Histiocytoma | | | 1 (2%) | |
| Tail, Melanoma Malignant | | 1 (2%) | | |

MUSCULOSKELETAL SYSTEM

| | | | | |
|-----------------|----------|----------|------|--------|
| Bone | (50) | (50) | (50) | (50) |
| Osteosarcoma | | | | 1 (2%) |
| Skeletal Muscle | (1) | (1) | (0) | (0) |
| Hemangiosarcoma | 1 (100%) | | | |
| Sarcoma | | 1 (100%) | | |

NERVOUS SYSTEM

| | | | | |
|------------------|------|------|------|------|
| Brain | (50) | (50) | (49) | (50) |
| Peripheral Nerve | (1) | (1) | (1) | (0) |
| Spinal Cord | (0) | (1) | (1) | (0) |

RESPIRATORY SYSTEM

| | | | | |
|--|--------|--------|--------|---------|
| Lung | (50) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Adenoma | | | | 1 (2%) |
| Alveolar/Bronchiolar Carcinoma | 1 (2%) | 2 (4%) | 2 (4%) | 3 (6%) |
| Hepatoblastoma, Metastatic, Liver | | | 1 (2%) | |
| Hepatocellular Carcinoma, Metastatic, Liver | 3 (6%) | 3 (6%) | 2 (4%) | 5 (10%) |
| Osteosarcoma, Metastatic, Bone | | | | 1 (2%) |
| Pheochromocytoma Malignant, Metastatic, Adrenal Medulla | | 1 (2%) | | |
| Sarcoma, Metastatic, Skin | 1 (2%) | | | |
| Nose | (50) | (50) | (50) | (50) |
| Adenoma | | 1 (2%) | | |
| Trachea | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

| B6C3F1 MICE FEMALE | 0 mg/kg | 200 mg/kg | 600 mg/kg | 2000 mg/kg |
|------------------------------|----------|-----------|-----------|------------|
| SPECIAL SENSES SYSTEM | | | | |
| Ear | (1) | (0) | (0) | (0) |
| Eye | (50) | (50) | (49) | (50) |
| Harderian Gland | (50) | (50) | (49) | (50) |
| Adenoma | 5 (10%) | 3 (6%) | 2 (4%) | 10 (20%) |
| Carcinoma | 1 (2%) | | 4 (8%) | 1 (2%) |
| URINARY SYSTEM | | | | |
| Kidney | (50) | (50) | (50) | (50) |
| Fibrous Histiocytoma | | | | 1 (2%) |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Fibrous Histiocytoma | | | | 1 (2%) |
| SYSTEMIC LESIONS | | | | |
| Multiple Organ | *(50) | *(50) | *(50) | *(50) |
| Histiocytic Sarcoma | 1 (2%) | 1 (2%) | 3 (6%) | 3 (6%) |
| Leukemia Myeloid | | | | 1 (2%) |
| Lymphoma Malignant | 11 (22%) | 9 (18%) | 7 (14%) | 2 (4%) |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Ginkgo biloba extract

Time Report Requested: 14:43:06

Route: GAVAGE

CAS Number: 90045-36-6

First Dose M/F: 03/17/05 / 03/18/05

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE

0 mg/kg

200 mg/kg

600 mg/kg

2000 mg/kg

Tumor Summary for Females

| | | | | |
|--|----|----|----|-----|
| Total Animals with Primary Neoplasms (b) | 35 | 46 | 46 | 49 |
| Total Primary Neoplasms | 67 | 79 | 90 | 135 |
| Total Animals with Benign Neoplasms | 25 | 39 | 41 | 48 |
| Total Benign Neoplasms | 32 | 48 | 48 | 63 |
| Total Animals with Malignant Neoplasms | 28 | 26 | 30 | 47 |
| Total Malignant Neoplasms | 35 | 31 | 42 | 72 |
| Total Animals with Metastatic Neoplasms | 4 | 5 | 3 | 6 |
| Total Metastatic Neoplasms | 4 | 5 | 3 | 7 |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | | |
| Total Animals with Neoplasms Uncertain- Benign or Malignant | | | | |
| Total Uncertain Neoplasms | | | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors